SERIF
LIVE

Serial Number

98638645

Owner

Flagship Labs 87, Inc.

Attorney

Christina M. Licursi

Filing Date

Jul 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SERIF Trademark

Serial Number: 98638645

SERIF is a trademark filed by Flagship Labs 87, Inc. on July 9, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Flagship Labs 87, Inc.

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

SERIF BIOMEDICINES, INC. (2 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

July 9, 2024

Registration Date

Not Registered

Published for Opposition

February 25, 2025

Goods & Services

Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services

Biological and chemical agents for scientific and research use, namely, nucleic acids for use in the manufacture of pharmaceuticals, reagents for pharmaceutical research purposes, and cells for scientific and research use

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Filing History

TEAS STATEMENT OF USE RECEIVED
Apr 17, 2026 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Apr 17, 2026 ERTD
SOU TEAS EXTENSION RECEIVED
Apr 17, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 18, 2025 EXRA
SOU EXTENSION 1 GRANTED
Oct 17, 2025 EX1G
SOU EXTENSION 1 FILED
Oct 17, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 17, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 22, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 2, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 2, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 2, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 30, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 29, 2024 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 9, 2024 NWOS
NEW APPLICATION ENTERED
Jul 9, 2024 NWAP